AG
CPRX

Algert Global’s Catalyst Pharmaceutical CPRX Stock Holding History

Algert Global’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-112,220
Closed -$2.21M – 1170
2025
Q3 		$2.21M Sell
112,220
-266,151
-70% -$5.47M 0.04% 655
2025
Q2 		$8.21M Buy
378,371
+329,981
+682% +$7.79M 0.17% 178
2025
Q1 		$1.17M Buy
48,390
+470
+1% +$10.6K 0.03% 738
2024
Q4 		$1M Buy
47,920
+31,115
+185% +$668K 0.02% 786
2024
Q3 		$334K Buy
16,805
+6,121
+57% +$113K 0.01% 975
2024
Q2 		$165K Buy
+10,684
New +$166K 0.01% 1319
2022
Q4 		– Sell
-29,545
Closed -$379K – 1155
2022
Q3 		$379K Buy
29,545
+3,455
+13% +$40.9K 0.02% 886
2022
Q2 		$183K Buy
+26,090
New +$191K 0.01% 1039

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Algert Global's CPRX Position: Q4 2025 in Review

Algert Global sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 112,220 shares — an estimated $2.21M sold.

Algert Global first reported a position in CPRX in Q2 2022 and held it in 8 quarters. The position peaked at $8.21M in Q2 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Algert Global reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Algert Global sold 112,220 Catalyst Pharmaceutical shares in Q4 2025, an estimated $2.21M.
  • Algert Global first reported a position in Catalyst Pharmaceutical in Q2 2022 and held it in 8 quarters.
  • Algert Global's Catalyst Pharmaceutical position peaked at $8.21M in Q2 2025.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Algert Global's 13F filing for Q4 2025, filed 17 Feb 2026.